img

Global Remicade (Infliximab) Monoclonal Antibody Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Remicade (Infliximab) Monoclonal Antibody Market Research Report 2024

Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.
According to Mr Accuracy reports’s new survey, global Remicade (Infliximab) Monoclonal Antibody market is projected to reach US$ 3855 million in 2034, increasing from US$ 2550 million in 2024, with the CAGR of 5.6% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Remicade (Infliximab) Monoclonal Antibody market research.
The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Remicade (Infliximab) Monoclonal Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


J & J
Pfizer
Organon
Amgen
Segment by Type
Brand
Biosimilar

Segment by Application


Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other

Consumption by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Remicade (Infliximab) Monoclonal Antibody report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Remicade (Infliximab) Monoclonal Antibody Market Overview
1.1 Product Overview and Scope of Remicade (Infliximab) Monoclonal Antibody
1.2 Remicade (Infliximab) Monoclonal Antibody Segment by Type
1.2.1 Global Remicade (Infliximab) Monoclonal Antibody Market Value Comparison by Type (2024-2034)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Remicade (Infliximab) Monoclonal Antibody Segment by Application
1.3.1 Global Remicade (Infliximab) Monoclonal Antibody Market Value by Application: (2024-2034)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Global Remicade (Infliximab) Monoclonal Antibody Market Size Estimates and Forecasts
1.4.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue 2018-2034
1.4.2 Global Remicade (Infliximab) Monoclonal Antibody Sales 2018-2034
1.4.3 Global Remicade (Infliximab) Monoclonal Antibody Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Remicade (Infliximab) Monoclonal Antibody Market Competition by Manufacturers
2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Manufacturers (2018-2023)
2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Manufacturers (2018-2023)
2.4 Global Remicade (Infliximab) Monoclonal Antibody Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Product Type & Application
2.7 Remicade (Infliximab) Monoclonal Antibody Market Competitive Situation and Trends
2.7.1 Remicade (Infliximab) Monoclonal Antibody Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Remicade (Infliximab) Monoclonal Antibody Players Market Share by Revenue
2.7.3 Global Remicade (Infliximab) Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Remicade (Infliximab) Monoclonal Antibody Retrospective Market Scenario by Region
3.1 Global Remicade (Infliximab) Monoclonal Antibody Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Remicade (Infliximab) Monoclonal Antibody Global Remicade (Infliximab) Monoclonal Antibody Sales by Region: 2018-2034
3.2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Region: 2018-2023
3.2.2 Global Remicade (Infliximab) Monoclonal Antibody Sales by Region: 2024-2034
3.3 Global Remicade (Infliximab) Monoclonal Antibody Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region: 2018-2034
3.3.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region: 2018-2023
3.3.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region: 2024-2034
3.4 North America Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.4.1 North America Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2034)
3.4.3 North America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.5.1 Europe Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2034)
3.5.3 Europe Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.6.1 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2034)
3.6.3 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.7.1 Latin America Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2034)
3.7.3 Latin America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.8.1 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2034)
3.8.3 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Type (2018-2034)
4.1.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Type (2018-2023)
4.1.2 Global Remicade (Infliximab) Monoclonal Antibody Sales by Type (2024-2034)
4.1.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Type (2018-2034)
4.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Type (2018-2034)
4.2.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Type (2018-2023)
4.2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Type (2024-2034)
4.2.3 Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Type (2018-2034)
4.3 Global Remicade (Infliximab) Monoclonal Antibody Price by Type (2018-2034)
5 Segment by Application
5.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Application (2018-2034)
5.1.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Application (2018-2023)
5.1.2 Global Remicade (Infliximab) Monoclonal Antibody Sales by Application (2024-2034)
5.1.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Application (2018-2034)
5.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Application (2018-2034)
5.2.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Application (2018-2023)
5.2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Application (2024-2034)
5.2.3 Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Application (2018-2034)
5.3 Global Remicade (Infliximab) Monoclonal Antibody Price by Application (2018-2034)
6 Key Companies Profiled
6.1 J & J
6.1.1 J & J Corporation Information
6.1.2 J & J Description and Business Overview
6.1.3 J & J Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.1.4 J & J Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.1.5 J & J Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Pfizer Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Organon
6.3.1 Organon Corporation Information
6.3.2 Organon Description and Business Overview
6.3.3 Organon Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Organon Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.3.5 Organon Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Corporation Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amgen Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.4.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Remicade (Infliximab) Monoclonal Antibody Industry Chain Analysis
7.2 Remicade (Infliximab) Monoclonal Antibody Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Remicade (Infliximab) Monoclonal Antibody Production Mode & Process
7.4 Remicade (Infliximab) Monoclonal Antibody Sales and Marketing
7.4.1 Remicade (Infliximab) Monoclonal Antibody Sales Channels
7.4.2 Remicade (Infliximab) Monoclonal Antibody Distributors
7.5 Remicade (Infliximab) Monoclonal Antibody Customers
8 Remicade (Infliximab) Monoclonal Antibody Market Dynamics
8.1 Remicade (Infliximab) Monoclonal Antibody Industry Trends
8.2 Remicade (Infliximab) Monoclonal Antibody Market Drivers
8.3 Remicade (Infliximab) Monoclonal Antibody Market Challenges
8.4 Remicade (Infliximab) Monoclonal Antibody Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Remicade (Infliximab) Monoclonal Antibody Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Remicade (Infliximab) Monoclonal Antibody Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Remicade (Infliximab) Monoclonal Antibody Market Competitive Situation by Manufacturers in 2024
Table 4. Global Remicade (Infliximab) Monoclonal Antibody Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Remicade (Infliximab) Monoclonal Antibody Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Remicade (Infliximab) Monoclonal Antibody Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Remicade (Infliximab) Monoclonal Antibody Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Remicade (Infliximab) Monoclonal Antibody, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Product Type & Application
Table 12. Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Remicade (Infliximab) Monoclonal Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Remicade (Infliximab) Monoclonal Antibody as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Remicade (Infliximab) Monoclonal Antibody Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Remicade (Infliximab) Monoclonal Antibody Sales by Region (2018-2023) & (K Units)
Table 18. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Region (2018-2023)
Table 19. Global Remicade (Infliximab) Monoclonal Antibody Sales by Region (2024-2034) & (K Units)
Table 20. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Region (2024-2034)
Table 21. Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Region (2018-2023)
Table 23. Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Region (2024-2034)
Table 25. North America Remicade (Infliximab) Monoclonal Antibody Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2023) & (K Units)
Table 27. North America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2024-2034) & (K Units)
Table 28. North America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Remicade (Infliximab) Monoclonal Antibody Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2023) & (K Units)
Table 32. Europe Remicade (Infliximab) Monoclonal Antibody Sales by Country (2024-2034) & (K Units)
Table 33. Europe Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Remicade (Infliximab) Monoclonal Antibody Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Remicade (Infliximab) Monoclonal Antibody Sales (K Units) by Type (2018-2023)
Table 51. Global Remicade (Infliximab) Monoclonal Antibody Sales (K Units) by Type (2024-2034)
Table 52. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Type (2018-2023)
Table 53. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Type (2024-2034)
Table 54. Global Remicade (Infliximab) Monoclonal Antibody Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Remicade (Infliximab) Monoclonal Antibody Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Type (2018-2023)
Table 57. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Type (2024-2034)
Table 58. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Type (2018-2023)
Table 59. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Type (2024-2034)
Table 60. Global Remicade (Infliximab) Monoclonal Antibody Sales (K Units) by Application (2018-2023)
Table 61. Global Remicade (Infliximab) Monoclonal Antibody Sales (K Units) by Application (2024-2034)
Table 62. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Application (2018-2023)
Table 63. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Application (2024-2034)
Table 64. Global Remicade (Infliximab) Monoclonal Antibody Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Remicade (Infliximab) Monoclonal Antibody Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Application (2018-2023)
Table 67. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Application (2024-2034)
Table 68. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Application (2018-2023)
Table 69. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Application (2024-2034)
Table 70. J & J Corporation Information
Table 71. J & J Description and Business Overview
Table 72. J & J Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. J & J Remicade (Infliximab) Monoclonal Antibody Product
Table 74. J & J Recent Developments/Updates
Table 75. Pfizer Corporation Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Pfizer Remicade (Infliximab) Monoclonal Antibody Product
Table 79. Pfizer Recent Developments/Updates
Table 80. Organon Corporation Information
Table 81. Organon Description and Business Overview
Table 82. Organon Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Organon Remicade (Infliximab) Monoclonal Antibody Product
Table 84. Organon Recent Developments/Updates
Table 85. Amgen Corporation Information
Table 86. Amgen Description and Business Overview
Table 87. Amgen Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Amgen Remicade (Infliximab) Monoclonal Antibody Product
Table 89. Amgen Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. Remicade (Infliximab) Monoclonal Antibody Distributors List
Table 93. Remicade (Infliximab) Monoclonal Antibody Customers List
Table 94. Remicade (Infliximab) Monoclonal Antibody Market Trends
Table 95. Remicade (Infliximab) Monoclonal Antibody Market Drivers
Table 96. Remicade (Infliximab) Monoclonal Antibody Market Challenges
Table 97. Remicade (Infliximab) Monoclonal Antibody Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Remicade (Infliximab) Monoclonal Antibody
Figure 2. Global Remicade (Infliximab) Monoclonal Antibody Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Remicade (Infliximab) Monoclonal Antibody Market Share by Type in 2024 & 2034
Figure 4. Brand Product Picture
Figure 5. Biosimilar Product Picture
Figure 6. Global Remicade (Infliximab) Monoclonal Antibody Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Remicade (Infliximab) Monoclonal Antibody Market Share by Application in 2024 & 2034
Figure 8. Ankylosing Spondylitis
Figure 9. Rheumatoid Arthritis
Figure 10. Crohn’s Disease
Figure 11. Other
Figure 12. Global Remicade (Infliximab) Monoclonal Antibody Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Remicade (Infliximab) Monoclonal Antibody Market Size (2018-2034) & (US$ Million)
Figure 14. Global Remicade (Infliximab) Monoclonal Antibody Sales (2018-2034) & (K Units)
Figure 15. Global Remicade (Infliximab) Monoclonal Antibody Average Price (US$/Unit) & (2018-2034)
Figure 16. Remicade (Infliximab) Monoclonal Antibody Report Years Considered
Figure 17. Remicade (Infliximab) Monoclonal Antibody Sales Share by Manufacturers in 2024
Figure 18. Global Remicade (Infliximab) Monoclonal Antibody Revenue Share by Manufacturers in 2024
Figure 19. The Global 5 and 10 Largest Remicade (Infliximab) Monoclonal Antibody Players: Market Share by Revenue in 2024
Figure 20. Remicade (Infliximab) Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 21. Global Remicade (Infliximab) Monoclonal Antibody Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 22. North America Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Country (2018-2034)
Figure 23. North America Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Country (2018-2034)
Figure 24. United States Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 25. Canada Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 26. Europe Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Country (2018-2034)
Figure 27. Europe Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Country (2018-2034)
Figure 28. Germany Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 29. France Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. U.K. Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. Italy Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Russia Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Region (2018-2034)
Figure 34. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Region (2018-2034)
Figure 35. China Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. Japan Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. South Korea Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. India Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Australia Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. China Taiwan Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Southeast Asia Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Latin America Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Country (2018-2034)
Figure 43. Latin America Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Country (2018-2034)
Figure 44. Mexico Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Brazil Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Argentina Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Country (2018-2034)
Figure 48. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Country (2018-2034)
Figure 49. Turkey Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Saudi Arabia Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. UAE Remicade (Infliximab) Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 52. Global Sales Market Share of Remicade (Infliximab) Monoclonal Antibody by Type (2018-2034)
Figure 53. Global Revenue Market Share of Remicade (Infliximab) Monoclonal Antibody by Type (2018-2034)
Figure 54. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Type (2018-2034)
Figure 55. Global Sales Market Share of Remicade (Infliximab) Monoclonal Antibody by Application (2018-2034)
Figure 56. Global Revenue Market Share of Remicade (Infliximab) Monoclonal Antibody by Application (2018-2034)
Figure 57. Global Remicade (Infliximab) Monoclonal Antibody Price (US$/Unit) by Application (2018-2034)
Figure 58. Remicade (Infliximab) Monoclonal Antibody Value Chain
Figure 59. Remicade (Infliximab) Monoclonal Antibody Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed